The initial Cannabis extract-based products, which are being manufactured, will be made available to licensed medical marijuana patients in Colorado. Later, the prodcuts will be expanded across the
According to the company, the funding comes on the heels of a recent $19m fundraising that was completed in April. CoDa develops and commerciales therapeutics for wound care,
MSDC-0602, an insulin sensitizer is selective for a molecular target, mTOT, which connects mitochondrial metabolism to important cell functions. Recent Phase 2a study in patients suffering with type
Heplisav when given as 2 doses over 4 weeks in modified intent to treat (MITT) analysis of adults with type II diabetes protected a greater proportion of subjects
The VSS technology is a computer vision technology consisting of Rfid sensors and software programs that utilize complex algorithms to process and analyze the imagery. The system detects
The SafeGuard is designed to provide life extendity to the analytical column without any compromises in the chromatographic performance. TraceGold GC Columns with SafeGuard are used in a
NCINIs inhibits HIV integrase by binding to a novel site and target the key component of the HIV virus. BI 224436 has been evaluated in a Phase 1a
The companies, under the licensing and Cooperative Research and Development Agreements (CRADA) will also develop a technology platform based on NCI’s cancer vaccine technology. In addition, Bavarian Nordic
Neratinib is a multi-targeted, irreversible tyrosine kinase inhibitor (TKI) oral drug which targets the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases. Neratinib is being studied in the
The new partnership includes recruitment and development of contract sales force specializing in medical food sales for lead therapeutic, Vascazen, a therapeutic by Pivotal. Pivotal Therapeutics president Rachelle
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.